@DrHaddadRobert Profile picture

Robert Haddad

@DrHaddadRobert

Division Chief, Head and Neck Oncology. Dana Farber Cancer Institute. McGraw Chair in Head and Neck Oncology Professor of Medicine. Harvard Medical School

Similar User
Robert Ferris, MD, PhD photo

@RobertFerrisMD

Ezra Cohen photo

@DrEzraCohen

Ravi Uppaluri, MDPhD photo

@DrUppaluri

AHNS photo

@AHNSinfo

Glenn J. Hanna, M.D. photo

@HeadNeckMD

Nancy Lee photo

@imrtlee

Nabil Saba, MD photo

@DrNabilSaba

Head and Neck Cancer International Group photo

@H_N_C_I_G

Karthik Rajasekaran photo

@RajasekaranMD

Umamaheswar Duvvuri MD PhD photo

@duvvuri_md

Neil D. Gross, MD, FACS photo

@DrNeilGross

John De Almeida photo

@DrJohndeAlmeida

Jonathan Schoenfeld photo

@jdschoenfeld1

José P. Zevallos, MD, MPH, FACS photo

@jpzevallos

Devraj Basu, MD, PhD, FACS photo

@BasuLab1

Robert Haddad Reposted

Doug is celebrating six years cancer-free this month! “When you have cancer, you say yes to things. You live life," he says. Your donation will help more patients like Doug become cancer-free. Let’s strike out cancer: jimmyfund.gives/KCANCER #KCANCER

Tweet Image 1

Robert Haddad Reposted

Thank you @RobGronkowski & @Edelman11 for a wonderful #pickleball game to benefit @DanaFarber @TheJimmyFund —we are in this together to beat Cancer ! @DanaFarber @DrHaddadRobert @DanaFarber_GU @DanaFarberNews @PanMass @goldietaylor

Tweet Image 1

Robert Haddad Reposted
Tweet Image 1

I’m teaming up with @DrHaddadRobert to play pickeball against @RobGronkowski and raise funds for cancer research for @DanaFarber ! Help us beat the Gronk (and Cancer!) charity.pledgeit.org/f/ozX6IMVf7v

Tweet Image 1


Robert Haddad Reposted

I’m teaming up with @DrHaddadRobert to play pickeball against @RobGronkowski and raise funds for cancer research for @DanaFarber ! Help us beat the Gronk (and Cancer!) charity.pledgeit.org/f/ozX6IMVf7v

Tweet Image 1

Robert Haddad Reposted

Out today--DC dysfunction in HNSCC antiPD1 resistance w/ a mechanistic role for CCL5 in enhancing DC function/ T cell priming. Congrats to Shin/Michi! @BrighamSurgery @DanaFarberNews @DrHaddadRobert @HeadNeckMD @jdschoenfeld1 tinyurl.com/686af9e9


Robert Haddad Reposted

First targeted therapy found safe and shows anti-tumor activity in patients with rare head and neck cancer. @DanaFarber's Robert Haddad, MD (@DrHaddadRobert) details the findings that were presented at #ESMO23.


Robert Haddad Reposted

.@sueyom, @DrHaddadRobert, Nicole C. Schmitt, Angela L. Ferguson, and Barbara A. Burtness discussed "Clinical Trials" in a plenary session today at the AACR-AHNS Head and Neck Cancer Conference. #aacrAHNS23

Tweet Image 1

Robert Haddad Reposted

This review discusses cisplatin ineligibility in pts with locally advanced #HNC #hncsm, summarizes the limited clinical evidence for adjuvant tx, & highlights ongoing clinical trials that have the potential to provide new tx options. sciencedirect.com/science/articl…

Tweet Image 1

Robert Haddad Reposted

1/ Results from #COSMIC-313 are out @NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by @CharlesSwanton @AndresC27622123 #ESMO22 Thread 🧵==> nejm.org/doi/full/10.10…

Tweet Image 1

TRIO Panel - Immunotherapy in H&N Cancer: What We Know, What We Think We Know and What We Really Don't. Join us tomorrow in Boston with the great ⁦@KaramLab⁩ ⁦@lucmorrisnyc⁩ and ⁦@MaieStJohn⁩ ⁦@__COSM⁩ ⁦@Triological⁩ . l.core-apps.com/cosm2023/event…


Finally out, our analysis from CONDOR/HAWK/EAGLE Tumor Mutational Burden as a Predictor of Survival With D+T in Recurrent Head and Neck Squamous Cell Carcinoma , also reporting on bTMB @RobertFerrisMD @AstraZenecaUS @DrEzraCohen @AACR @DrUppaluri aacrjournals.org/clincancerres/…


Our paper on CT performance with ENE shows poor reproducibility among expert head/neck neuroradiologists and poor predictive value for histologic ENE rdcu.be/c42sc. @BenjaminKannMD @sueyom @DanaFarberNews @BWHRadEdu @BrighamWomens @DrVijayPatil11


Robert Haddad Reposted

Key question for trials is whether folks are comfortable randomizing to RT alone. The vote by @DrHaddadRobert suggests only a quarter of us are willing but hopefully@more in the context of a trial for a cleaner answer

Great question! Need voting options for weekly cisplatin and also why pt is cisplatin ineligible (some criteria are softer than others), but we need trials adding novel agents to RT and the highest vote count comes without level I data.



Pembrolizumab versus Cetuximab concurrent with radiotherapy in patient... sciencedirect.com/science/articl… No difference in outcomes.We still need to define SOC for cis ineligible pts . what is yours ? @DrNabilSaba @DavidSherMD @RobertFerrisMD @seanmmcbride


Loading...

Something went wrong.


Something went wrong.